CME credits: 1.00

Valid until: 01-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/current-guidelines-and-real-world-evidence-for-ros1-testing-in-nsclc/18154/

This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.